Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

  • Michael Gnant
  • , Georg Pfeiler
  • , Günther G Steger
  • , Daniel Egle
  • , Richard Greil (Co-author)
  • , Florian Fitzal
  • , Viktor Wette
  • , Marija Balic
  • , Ferdinand Haslbauer
  • , Elisabeth Melbinger-Zeinitzer
  • , Vesna Bjelic-Radisic
  • , Raimund Jakesz
  • , Christian Marth
  • , Paul Sevelda
  • , Brigitte Mlineritsch (Co-author)
  • , Ruth Exner
  • , Christian Fesl
  • , Sophie Frantal
  • , Christian F Singer

Research output: Contribution to journalOriginal Articlepeer-review

182 Citations (Web of Science)
Original languageEnglish
Pages (from-to)339-351
JournalLANCET ONCOL
Volume20
Issue number3
DOIs
Publication statusPublished - 2019

Keywords

  • PLUS ZOLEDRONIC ACID
  • CLINICAL-PRACTICE
  • BONE LOSS
  • THERAPY
  • WOMEN
  • BISPHOSPHONATES
  • INHIBITOR
  • RANKL
  • METAANALYSIS
  • PREVENTION

Cite this